- /
- Supported exchanges
- / US
- / MKGAF.PINK
MERCK Kommanditgesellschaft auf Aktien (MKGAF PINK) stock market data APIs
MERCK Kommanditgesellschaft auf Aktien Financial Data Overview
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get MERCK Kommanditgesellschaft auf Aktien data using free add-ons & libraries
Get MERCK Kommanditgesellschaft auf Aktien Fundamental Data
MERCK Kommanditgesellschaft auf Aktien Fundamental data includes:
- Net Revenue: 21 219 M
- EBITDA: 5 953 M
- Earnings Per Share: 7
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: 2.14
Get MERCK Kommanditgesellschaft auf Aktien End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MERCK Kommanditgesellschaft auf Aktien News
New
United States Lipid Nanoparticle Market Forecast and Competitive Analysis Report 2025-2033 Featuring Merck, Evonik, Genevant Sciences, CordenPharma, Arcturus, Ascendia, Acuitas, Croda
Company Logo The United States lipid nanoparticle market is projected to expand from $210.34 billion in 2024 to $519.18 billion by 2033, with a CAGR of 10.56%. This growth is driven by the increasing...
Trump administration prepares probe targeting global drug pricing — FT
[Visiting Australian Prime Minister Anthony Albanese Meets With Trump At The White House] Kevin Dietsch/Getty Images News The Trump administration is preparing to launch a new investigation under Sec...
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
SpringWorks Therapeutics, Inc. Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement i...
Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed?
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, Ba...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.